A Phase 3 trial funded by AbbVie shows tavapadon improves early Parkinson's symptoms

A Phase 3 trial funded by AbbVie demonstrates that a once daily pill called tavapadon significantly improves movement and daily functioning in people with early Parkinson's. Results from a major clinical trial published in The Lancet Neurology show that an experimental oral treatment called tavapadon offers substantial relief from movement challenges and daily living difficulties for people in the early stages of Parkinson's. The Phase 3 trial, known as TEMPO 2, evaluated how well a flexible daily dose of the medication worked over a six month period. Sponsored by the pharmaceutical company AbbVie, the study provides strong evidence that this new class of treatment could soon become a valuable option for managing symptoms. The TEMPO 2 trial involved 304 adults who had been diagnosed with Parkinson's within the preceding three years, with roughly two thirds diagnosed less than twelve months before joining the study. Researchers set up a double blind, placebo controlled trial across 75 international centres, meaning neither the participants nor the doctors knew who received tavapadon and who received an inactive placebo pill. Over 27 weeks, participants took their assigned treatment once each day. Those taking tavapadon started at a dose of 5 milligrams daily, which doctors gradually adjusted up to 15 milligrams based on how well each person tolerated the medicine. Tavapadon works in a distinctly different way from traditional Parkinson's treatments. Rather than flooding the brain with dopamine precursor chemicals like levodopa or broadly stimulating D2 and D3 brain receptors like existing dopamine agonists, tavapadon acts as a selective partial agonist that specifically targets D1 and D5 receptors. These particular receptors cluster in regions of the brain responsible for movement control. By activating D1 and D5 receptors in a precise, partial manner, tavapadon mimics natural dopamine signals to smooth out movement while avoiding the overstimulation that can cause involuntary movements, known as dyskinesia. To judge how effectively tavapadon eased symptoms, researchers relied on a standardised rating scale that measures physical symptoms, such as stiffness or tremors, alongside a person's ability to carry out everyday activities, such as dressing, eating, or walking. At the start of the study, participants had an average combined score of 30.5 points. After six months, scores among individuals taking tavapadon dropped by an average of 10.3 points, compared to a reduction of just 1.2 points among those taking the placebo. This marked difference represented a clear, meaningful improvement in physical coordination and daily independence, with positive changes appearing as early as the fifth week of treatment. When participants assessed their own progress through self reporting measures, 46 percent of those receiving tavapadon described their condition as much improved or very much improved, compared to only 19 percent in the placebo group. Overall, nearly eight out of ten people on tavapadon reported at least minimal improvement. Regarding safety and tolerability, most side effects reported during the study were mild to moderate, occurring most frequently while doctors were gradually adjusting the dose. The most common issues were nausea, headaches, and dizziness. About 24 percent of individuals taking tavapadon stopped treatment early due to side effects, compared to 4 percent in the placebo group. Crucially, the trial recorded very low rates of severe daytime sleepiness or impulse control problems, which are two notoriously difficult side effects frequently linked to older dopamine agonists. Following these positive findings across the TEMPO clinical development programme, AbbVie has submitted a formal application for regulatory approval, bringing this novel therapy closer to wider availability.